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cientiﬁc comment
regnancy  in sickle  cell  disease  – do we know what
o expect?leber Yotsumoto Fertrin
zil
studies should focus on transfusional management of theseniversidade Estadual de Campinas (UNICAMP), Campinas, SP, Bra
regnancy in patients with sickle cell disease (SCD) has
lways been a challenge for both hematologists and
bstetricians. Although increasing knowledge on the complex
athophysiology of the sickle vaso-occlusive process has
nabled better characterization of the endothelial dysfunction
n SCD and how different genotypes present with varying
egrees of severity, physicians can still not be sure of the
utcome of a pregnancy in a given patient based solely on
he baseline assessment outside of the pregnancy setting –
bstetricians have frequently been surprised by how severely
ll pregnant patients with SCD can get, even though they had
ever had life-threatening complications previously.
SCD predisposes pregnant women to a large number of
omplications, such as a higher incidence of eclampsia,
reterm labor and delivery, deep venous thrombosis,
ntrauterine growth restriction, urinary tract infections,
epsis, etc.1 While it is understandable that widespread sickle
asculopathy can contribute to poor pregnancy outcomes,
cientiﬁc literature on both the pathophysiology of these
omplications in SCD pregnancies and evidence-based
ecommendations for the proper management of these
atients are still lacking.
A clear example is the concept that hydroxyurea (HU)
hould not be used in pregnant women, and that its use
hould be interrupted once pregnancy is conﬁrmed.2 This
s easily accepted by physicians, but evidence for such
ecommendations is largely based on animal studies using
ery high doses of HU, and a careful review of the literature
o far has failed to prove increased risk of birth defects in
regnant women taking HU.3 Without HU as a therapeutic
ption, management of pregnant patients with SCD is limited
DOI of original article: http://dx.doi.org/10.1016/j.bjhh.2014.07.002.
 See paper by Silva-Pinto AC et al. on pages 329–33.
Corresponding author at: Clinical Pathology Department, Universidade
niversitária Prof. Zeferino Vaz, 13083-878 Distrito de Barão Geraldo, C
E-mail address: fertrin@unicamp.br (K.Y. Fertrin).
ttp://dx.doi.org/10.1016/j.bjhh.2014.07.017
516-8484/© 2014 Associac¸ão Brasileira de Hematologia, Hemoterapia
eserved.to blood transfusion. Reports have been mostly limited to
case series, with only a few published prospective studies
addressing transfusion strategies.4,5 In this regard, there is
neither consensus on how to decide which patients should
be transfused nor are there studies that investigate how
and at what time point during the pregnancy this would be
ideal. Gilli et al. have previously reported favorable outcomes
in SCD patients that were systematically subjected to
erythrocytapheresis by 28 weeks of gestation.6 Similarly, the
article by Silva-Pinto et al. in this issue of the Revista Brasileira
de Hematologia e Hemoterapia (RBHH) joins the voices of
several other publications that present data associating
transfusion with better fetal and maternal outcomes.7
Statistical signiﬁcance is hard to come by because pregnancy
in SCD is still a relatively rare event in a single institution.
While only one randomized, prospective trial showed no
beneﬁt in reducing pregnancy-related complications or fetal
growth impairment with prophylactic transfusions, there
was a signiﬁcant reduction in the incidence of vaso-occlusive
crises.
With the current effort toward better quality of life for SCD
patients, and the perspective of new therapies to increase life
expectancy in this population, there is need for multicentric
collaboration to obtain better evidence on how to manage this
special population of pregnant women. Since teratogenicity
of fetal hemoglobin inducers will most probably preclude the
design of clinical trials involving pregnant women, prospective Estadual de Campinas (Unicamp), Rua Carlos Chagas, 450, Cidade
ampinas, SP, Brazil.
patients, evaluating both obstetric and hematologic outcomes.
Until then, physicians will still not know what to expect when
their patients are expecting.
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